Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CM1C | ISIN: US75629V1044 | Ticker-Symbol:
NASDAQ
21.01.25
21:59 Uhr
6,880 US-Dollar
0,000
0,00 %
1-Jahres-Chart
RECURSION PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
RECURSION PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur RECURSION PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
SaRecursion Pharmaceuticals, Inc. (RXRX): Revolutionizing Drug Discovery with AI and Strategic Collaborations for Strong Growth24
RECURSION PHARMACEUTICALS Aktie jetzt für 0€ handeln
FrIs Recursion Pharmaceuticals Stock a Buy?29
13.01.CEO von Recursion Pharmaceuticals verkauft Aktien im Wert von 287.200 US-Dollar74
13.01.RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report22
09.01.Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3.1% Following Analyst Downgrade24
07.01.Recursion advances two cancer drug trials30
07.01.Recursion treibt zwei Krebsmedikamenten-Studien voran52
07.01.Recursion Pharmaceuticals: Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More191REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitorsREC-4539...
► Artikel lesen
02.01.Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 8.1% - Still a Buy?26
01.01.Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 0.1% - Should You Sell?12
21.12.24Is Recursion Pharmaceuticals Stock a Millionaire Maker?55
20.12.24Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules257Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug...
► Artikel lesen
17.12.24RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report23
15.12.24Jim Cramer Says He Was Wrong on NVIDIA Holding Recursion Pharmaceuticals (RXRX)98
12.12.24Recursion Pharmaceuticals' (RXRX) AI-Driven Cancer Treatment Shows Promise in Early Trials17
11.12.24Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - Time to Buy?13
10.12.24Unpacking the Latest Options Trading Trends in Recursion Pharmaceuticals15
10.12.24Recursion Pharmaceuticals, Inc.: Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability205REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagementConfirmed...
► Artikel lesen
06.12.24Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 6.7% Higher - Should You Buy?32
06.12.24Recursion Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:RXRX)36
Seite:  Weiter >>
122 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
3,1,3